As the industry settles into a wary comfort zone with the draft guidelines around social media issued in January, we review the changes and look to what lies ahead in terms of risk and opportunities for pharma’s engagement in social media.
One of the most notable changes is that the FDA makes it clear that drug companies are not responsible for random user-generated content, but they can be held responsible for their response to such content. If a person with no connection to a drug maker mentions a drug by name on its Facebook page or other social media outlet, the drug…
FDA Violations on Social Media
Summary of FDA Draft Guidelines